US20160256692A1 - Combined vagus-phrenic nerve stimulation device - Google Patents
Combined vagus-phrenic nerve stimulation device Download PDFInfo
- Publication number
- US20160256692A1 US20160256692A1 US15/018,973 US201615018973A US2016256692A1 US 20160256692 A1 US20160256692 A1 US 20160256692A1 US 201615018973 A US201615018973 A US 201615018973A US 2016256692 A1 US2016256692 A1 US 2016256692A1
- Authority
- US
- United States
- Prior art keywords
- stimulation
- pulse generator
- nerve
- implantable pulse
- respiration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0826—Detecting or evaluating apnoea events
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
- A61N1/36139—Control systems using physiological parameters with automatic adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
- A61N1/0558—Anchoring or fixation means therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3601—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
- A61N1/3614—Control systems using physiological parameters based on impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0809—Detecting, measuring or recording devices for evaluating the respiratory organs by impedance pneumography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1116—Determining posture transitions
Abstract
An implantable pulse generator (IPG) includes a respiration activity sensing unit configured to generate a signal representing respiration activity, a stimulation unit configured to generate nerve stimulation electric pulses, and a control unit configured to trigger delivery of the nerve stimulation electric pulses via a stimulation electrode on a stimulation lead connected to the implantable pulse generator. The triggering of the stimulation pulse delivery depends on the signal representing respiration activity.
Description
- This application claims priority under 35 USC §119(e) to U.S.
Provisional Patent Application 62/127,296 filed 3 Mar. 2015, the entirety of which is incorporated by reference herein. - The invention relates to an implantable stimulation system suitable for vagus nerve stimulation, the system including an implantable pulse generator (IPG) having a stimulation lead connected to the IPG, and which has a stimulation electrode for delivery of stimulation pulses. Preferably, the system is suitable for Vagus-Phrenic Nerve Stimulation (VNS-PhrNS) therapy, in particular for the treatment of patients suffering from Congestive Heart Failure (CHF) with Central Sleep Apnea (CSA) syndrome.
- Transvascular stimulation of a vagus nerve via a catheter, for the purpose of heart rate reduction (parasympathetic drive), was first reported by Thompson et al. in 1998 [Thompson et al. “Bradycardia induced by intravascular versus direct stimulation of the vagus nerve”, Annals of Thoracic Surgery, 65(3), 637-42, 1998]. A few years later, Hasdemir et al. [Hasdemir et al. “Endovascular stimulation of autonomic neural elements in the superior vena cava using a flexible loop catheter”, Japanese Heart Journal, 44(3), 417-27, 2003] investigated the use of a flexible loop with multiple contacts in the superior vena cava (SVC). This work showed stimulation at anterior sites resulted in phrenic nerve stimulation, whereas posterior site stimulation affected sinus cycle length and atrioventricular conduction while avoiding phrenic nerve stimulation.
- Transvascular stimulation of the phrenic nerves, on the other hand, dates back to the 1950s [Doris J. W. Escher et al. “Clinical control of respiration by transvenous phrenic pacing”, Trans. Amer. Soc. Artif. Int. Organs, Vol. XIV, 192-197, 1968]. WO2008/092246 A1 discloses a stimulation device with a single endovascular lead having multiple electrodes for stimulation of a vagus nerve and/or a phrenic nerve. The reference describes phrenic nerve stimulation to regulate breathing, and fine-tuning the positioning of the electrode array in the internal jugular vein (UV) by observing the patient's breathing.
- U.S. Pat. No. 8,433,412 B1 discloses a lead-electrode system for use with an Implantable Medical Device (IMD) configured to monitor and/or treat both cardiac and respiratory conditions. More particularly, versions of the invention relate to a lead-electrode configuration of a combination IMD that combines therapies such as cardiac pacing, respiratory sensing, phrenic nerve stimulation, defibrillation, and/or biventricular pacing, referred to as Cardiac Resynchronization Therapy (CRT). Stimulation and/or sensing leads may be placed in a small pericardiophrenic vein, a brachiocephalic vein, an azygos vein, a thoracic intercostal vein, or other thoracic vein that affords proximity to the phrenic nerve for stimulation. Respiration sensing may be performed via transthoracic impedance.
- U.S. Pat. No. 8,630,704 B2 discloses utilizing measurement of respiratory stability or instability during sleep or rest as feedback to control stimulation of an autonomic neural target (e.g. vagus nerve stimulation).
- Almost half of the Congestive Heart Failure (CHF) patient population suffers from Central Sleep Apnea (CSA). Although CRT has become the standard device therapy for the treatment of NYHA class III or IV heart failure patients with left ventricular ejection fractions (LVEF)≦35% and QRS≧130 ms, only 7% of all eligible CHF patients receive the device (see http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493802/), and approximately 30% of those who receive it are classified as non-responders (see http://circ.ahajournals.org/content/117/20/2608.abstract). Hence, a combination device as proposed by U.S. Pat. No. 8,433,412 B1 is not optimal for the treatment of CHF with CSA.
- Vagus nerve stimulation recently emerged as a potential progression-preventing and treatment option for CHF patients. Experimental data have demonstrated that stimulation of a vagus nerve at the cervical level is able to reverse ventricular remodeling of the failing heart. There is also evidence that increasing parasympathetic activity may stimulate the production of nitric oxide, and reduce the devastating inflammatory process involved in heart failure. Present vagus nerve stimulation devices for CHF involve an implanted nerve cuff electrode that connects via wires to an IPG in the patient's chest. A standard pacemaker sensing lead in the ventricle has been proposed in prior art for the purpose of synchronous delivery of vagus nerve stimulation pulses in the cardiac refractory period, although other prior art devices operate asynchronously to the cardiac cycle. Stimulation of both the right and left vagus nerves are disclosed in prior art for CHF treatment.
- At the cervical level, the vagus nerve bundle includes large-diameter fibers that innervate the muscles of the larynx and pharynx in addition to the target parasympathetic cardiac fibers. Since the former present a lower threshold to stimulation compared to the latter, vagus nerve stimulation therapy delivery for CHF requires the use of special waveforms and electrode arrangements that preferentially target the cardiac fibers. Although side effects (e.g. coughing) are reduced with these special stimulation techniques, they are not fully eliminated, which is a drawback of this stimulation approach.
- Transvascular stimulation of the vagus nerve cardiac branches is very appealing, as the implantation of endovascular leads is well known by physicians dealing with CHF patients. Chronically implanting a lead in a large major vein as proposed by WO2008/092246 A1 requires a suitable anchoring solution which is not described in that reference. Unfortunately, the absence of data supporting the safety and efficacy of SVC filters for upper-extremity Deep Vein Thrombosis (DVT) (see http://www.jvir.org/article/S1051-0443%2810%2900208-3/abstract) have precluded the chronic implantation of endovascular leads in large veins for the purpose of nerve stimulation. There is no suitable solution in the prior art that satisfactorily addresses this issue.
- U.S. Pat. No. 8,433,412 B1 does not disclose stimulation of the vagus nerve cardiac branches, though this is possible via a lead in the left superior intercostal or azygos vein. In that reference, an “implantable respiration lead” is proposed for transvascularly stimulating a phrenic nerve. This respiration lead may be installed in a pericardiophrenic vein, a brachiocephalic vein, an IJV, a superior intercostal vein, the SVC, or other appropriate locations.
- The invention seeks to provide a nerve stimulation device that advances the management/treatment of Congestive Heart Failure (CHF) patients, in particular those who also suffer from Central Sleep Apnea (CSA) syndrome.
- The invention also seeks to provide a dual-purpose implantable system for Vagus-Phrenic Nerve Stimulation (VNS-PhrNS) based on a single endovascular lead and implantable pulse generator (IPG), particularly targeting CHF patients with CSA syndrome, and suitable for integration into a Home Monitoring/Remote Programming therapy regime.
- An exemplary version of the invention involves an IPG that is connected or connectable to a stimulation lead having at least one stimulation electrode. This IPG includes a respiration activity sensing unit configured to generate a signal that represents respiration activity (such as a chest Respiration Effort Signal (REFFS)), and at least one stimulation unit configured to generate electric stimulation pulses for nerve stimulation. The IPG further includes a control unit configured to trigger delivering of electric stimulation pulses via the stimulation electrode(s), wherein triggering of the stimulation pulses depends on the signal that represents respiration activity.
- Preferably, the control unit is configured to generate a predictive respiration pattern from the signal that represents respiration activity, and to trigger the stimulation pulses depending on the predictive respiration pattern.
- Stimulation pulses can be delivered in anticipation of a physiological event in the respiration pattern that can be predicted from the chest Respiration Effort Signal (REFFS) or other respiration activity signal. Preferably, the delivery of stimulation occurs during a breathing pause period.
- The control unit can be configured to trigger the stimulation pulses using the predictive respiration pattern as feed-forward parameter.
- Preferably, the stimulation lead has several stimulation electrodes for delivery of stimulation pulses. The control unit is configured to select one or more of the electrodes, and to trigger delivery of electric stimulation pulses via the selected electrodes. This delivery may be triggered when the signal that represents respiration activity indicates a breathing pause.
- The invention reflects the view that an implantable chronic therapy for combined CHF-CSA treatment via VNS-PhrNS should preferably utilize a single endovascular lead that is implanted through typical pacemaker-lead access sites (e.g. the subclavian vein), and that avoids routing through the superior vena cava (SVC) to allow for the possibility of implanting a Cardio Rhythm Management (CRM) device should the patient require one in the future. This makes the azygos vein less of a candidate, in particular because implantable cardioverter defibrillator (ICD) leads, for example, are also implanted in the azygos vein in patients who present a high threshold to defibrillation stimulation (Bar-Cohen et al. “Novel use of a vascular plug to anchor an azygous vein ICD lead”, Journal of Cardiovascular Electrophysiology, 21(1), 99-102, 2010). The left superior intercostal vein is then the preferred location for the placement of this VNS-PhrNS combo lead. However, given the proximity of the vagus branches and phrenic nerve in this location, there is a need for a suitable therapy delivery strategy which manages stimulation spillage.
- The stimulation lead is preferably a single multi-electrode lead that can be implanted in the left superior intercostal vein, and which is connectable to the IPG that can be located in a pocket in the patient's chest.
- The chest Respiration Effort Signal (REFFS) is preferably either derived by an accelerometer in the IPG, or by impedance measurement between the IPG case and one of the lead electrodes. Accordingly, it is preferred if the respiration activity sensing unit includes or is connected to an accelerometer, and wherein the respiration activity sensing unit is configured to evaluate an accelerometer signal to generate the chest REFFS. Alternatively, the respiration activity sensing unit can include or can be connected to an impedance measurement unit that generates an impedance signal that represents intrathoracic impedance, and wherein the respiration activity sensing unit is configured to evaluate the impedance signal to generate the chest REFFS.
- The Respiration Effort Signal (REFFS) is preferably used as feed-forward parameter for the delivery of Vagus Nerve Stimulation (VNS) therapy so that any stimulation spillage to the phrenic nerve will assist breathing.
- The IPG is preferably connected or connectable to a stimulation lead having several stimulation electrodes. The control unit of the IPG is preferably configured to trigger delivery of electric stimulation pulses via selected electrodes, wherein triggering of the stimulation pulses depends on the chest REFFS.
- The IPG is preferably configured to perform intrathoracic far-field electrogram (ff-EGM) recordings for CHF monitoring, and to detect hypopnea and apnea conditions based on changes to the chest Respiration Effort Signal (REFFS). Upon detection of one of these conditions, Phrenic Nerve Stimulation (PhrNS) can be delivered to restore normal breathing.
- The IPG can also include a heart monitoring unit that is configured to determine parameters such as heart rate.
- The IPG may further include a ff-EGM sensing unit that is connected to an electrically conducting case of the IPG, and to one or more stimulation electrodes of the stimulation lead, wherein the ff-EGM sensing unit is configured to sense and evaluate ff-EGM signals.
- The device can operate in a stimulation mode where the chest Respiration Effort Signal (REFFS) is also used as a feed-forward parameter for the delivery of Phrenic Nerve Stimulation (PhrNS) therapy. This mode may minimize diaphragm atrophy if the patient is hospitalized and placed on mechanical ventilation.
- The IPG might include a telemetry unit allowing it to communicate via a MICS-band link to an external Programmer, or to a bedside Patient Messenger connected to a Home Monitoring/Remote Programming Center.
- The stimulation lead is preferably a percutaneous, linear-type multi-electrode lead configured for placement in a left superior intercostal vein. The inventors found that the left superior intercostal vein provides a superior location for the dual stimulation of the left phrenic nerve and the cardiac branches of the left vagus nerve. Implantation of a lead in the left superior intercostal vein can be done through the left subclavian vein, and the lead can be connected to an IPG in a pocket in the left side of the patient's chest. Several electrodes (e.g. eight, similar to a percutaneous spinal cord lead) are preferred for easy lead placement to achieve selective stimulation.
- The invention also involves a method for nerve stimulation including the steps of monitoring respiration activity; determining a predictive respiration pattern based on the monitored respiration activity; and delivering stimulation pulses depending on the monitored respiration activity and/or the predictive respiration pattern for delivering the stimulation pulses. The stimulation pulses are preferably delivered to a vagus nerve and/or a phrenic nerve. The pulse delivery preferably occurs during a breathing pause.
- Preferably, the chest Respiration Effort Signal (REFFS) is derived by either an accelerometer in the IPG, or by impedance measurement between an electrode in the lead and the IPG case.
- Given the proximity of the nerve branches, the chest Respiration Effort Signal (REFFS) is preferably used as a feed-forward parameter for the delivery of Vagus Nerve Stimulation (VNS) therapy so that any stimulation spillage to the phrenic nerve, should it occur, is timed to assist breathing. Preferably, VNS is delivered during the breathing pause period derived from the chest REFFS.
- The IPG may be configured so it can record the far-field electrogram (ff-EGM) utilizing a vector between an electrode in the lead and the IPG case. The ff-EGM can be utilized for heart rate determination and heart condition monitoring. Preferably, the IPG includes a ff-EGM sensing unit configured to sense and to evaluate far-field electrogram signals, and which is connected to an electrically-conducting area of the IPG case and to at least one stimulation electrode of the stimulation lead.
- Given apneas can occur at any time of day if the patient falls asleep, monitoring and detection of such events is preferably performed independently of the time of day. Preferably, the control unit is configured to deliver Phrenic Nerve Stimulation (PhrNS) therapy upon detection of a hypopnea or an apnea condition from the chest Respiration Effort Signal (REFFS), i.e. shallow breathing effort or absence of breathing effort respectively, to re-establish normal breathing. Although the arrangement of electrodes and stimulation technique for PhrNS will minimize spillage to the vagus nerve (e.g. guarded cathode configuration), spillage is actually beneficial for CHF as both are in the same frequency range.
- Preferably, the IPG includes a triaxial accelerometer. The triaxial capabilities of the accelerometer permit monitoring sleeping positions at night time. This statistic is of particular interest as patients with CHF generally tend to sleep in a sitting position due to breathing difficulties (e.g., when the lungs fill with fluid). Trend data on sleeping positions, for example, can be utilized to analyze improvement or worsening of a patient's condition. This trend, together with CSA event statistics and detected heart conditions derived from the far-field electrogram (ff-EGM) (e.g. arrhythmias), can be telemetered via a MICS-link to a bedside Patient Messenger which is connected to a Home Monitoring/Remote Programming Center. The same wireless link can be used for programming of the IPG via an external Programmer.
-
FIG. 1 shows an exemplary implantable stimulation system; -
FIG. 2 shows the system ofFIG. 1 in combination with external devices; -
FIG. 3 is a schematic block diagram of components of an implantable pulse generator (IPG) for use in the system ofFIG. 1 or 2 ; -
FIG. 4 is a more detailed view of the implanted multi-electrode lead ofFIG. 1 in the left superior intercostal vein; -
FIG. 5 illustrates an alternative version for the lead wherein the four distal electrodes are implemented with opposite active areas; -
FIG. 6 illustrates a preferred stimulation arrangement for the electrodes; -
FIG. 7 illustrates that the chest Respiration Effort Signal (REFFS) in a CHF patient with CSA alternates between two breathing patterns; and -
FIG. 8 shows that the mean power at the IPG implant sites (i.e. somewhere between 9-a and 10-a) is 20 dB below the maximum measured at the 11-a position (ideal chest position). -
FIG. 1 shows an implantable stimulation system including astimulation lead 100 and an implantable pulse generator (IPG) 106 with aheader 22. Thestimulation lead 100 is a percutaneous, linear-type multi-electrode lead, which is implanted in the left superiorintercostal vein 101 via thesubclavian vein 102 using standard pacemaker implantation techniques.Electrodes 107 of thelead 100 form an active contact for the delivery of stimulation pulses and/or for impedance measurement. Thestimulation lead 100 is positioned in thevein 101 so that electrodes are distributed between thephrenic nerve 103 and thevagus nerve 104, which cross the left superiorintercostal vein 101. Thelead 100 has adistal anchoring mechanism 105, and its proximal end is routed subcutaneously and connected to anIPG 106 implanted in the patient's chest. -
FIG. 2 illustrates a preferred system that further includes abedside Patient Messenger 601 and aProgrammer 604, external devices which communicate with theIPG 106. TheIPG 106 can wirelessly communicate with thePatient Messenger 601 via a MICS-band link 602, which can further relay the information to a Home Monitoring/Remote Programming Center. Asimilar link 603 allows theProgrammer 604 to program theIPG 106. -
FIG. 3 is a schematic diagram of some of the components of theIPG 106. TheIPG 106 includes a case (IPG case) 20 and a header 22 (seeFIG. 1 ) for connection of thelead 100. Theheader 22 includes a number ofconnectors stimulation lead 100, and thus to theelectrodes 107 of thestimulation lead 100. - Within the
IPG case 20, one ormore stimulation units connectors respective connector stimulation unit 36 to 46 for eachconnector 24 to 34 (and thus for eachelectrode 107 of lead 100), one stimulation unit and a switch matrix can be provided, whereby the switch matrix allows delivery of stimulation pulses via selected connectors (and thus via selectedelectrodes 107 of lead 100). In another version of the illustrated arrangement, allelectrodes 107 oflead 100 are switched in parallel to each other, and thus only one connector and one stimulation unit is needed. - In the version of
FIG. 3 , eachstimulation unit control unit 50. Thecontrol unit 50 controls generation, and triggers delivery, of stimulation pulses by thestimulation units stimulation unit - The
control unit 50 is further connected to atime signal generator 52 that supplies a time base to thecontrol unit 50. - The
IPG 106 further includes anactivity sensing unit 54, preferably a three-axis accelerometer for sensing movements of theIPG 106 in three spatial dimensions, which delivers an accelerometer signal to thecontrol unit 50. - The
control unit 50 is also connected to a far-field electrogram (ff-EGM)sensing unit 56 configured to generate a ff-EGM signal representing a far-field electrogram 600. In order to record such a signal, the ff-EGM sensing unit 56 is connected to at least one of theconnectors 24 to 34, and thus to one of theelectrodes 107 oflead 100. Another input of the ff-EGM sensing unit 56 is connected to theIPG case 20. Thus, the ff-EGM sensing unit 56 can sense voltages between anelectrode 107 and theIPG case 20 that result from electric potentials caused by the patient's heart activity. The far-field electrogram (ff-EGM)sensing unit 56 is configured to supply a ff-EGM signal to thecontrol unit 50 wherein the ff-EGM signal represents the patient's heart activity. The patient's heart rate and other parameters can be determined from the ff-EGM signal. - The
control unit 50 is further connected to animpedance measuring unit 60 that includes a programmablecurrent source 62 for generating and delivering biphasic impedance measuring pulses. Thecurrent source 62 may be electrically connected to theIPG case 20 and to at least one of theconnectors 24 to 34 (and thus to at least one of theelectrodes 107 of lead 100). Theimpedance measurement unit 60 further includes avoltage sensing unit 64 configured to measure a voltage difference between anelectrode 107 oflead 100 and theIPG case 20, or between twoelectrodes 107, in response to delivery of current pulses by thecurrent source 62. Thecurrent source 62 and thevoltage sensing unit 64 are connected to an impedance determination unit 66 of theimpedance measurement unit 60. The impedance determination unit 66 is configured to generate an impedance signal depending on the voltages measured byvoltage sensing unit 64, and to supply the impedance signal to thecontrol unit 50. The impedance signal generated by theimpedance measurement unit 60 represents an intrathoracic impedance which depends on the breathing activity of a patient. Thus, thecontrol unit 50 can determine the chest Respiration Effort Signal (REFFS) from the impedance signal supplied by theimpedance measurement unit 60. Alternatively, as discussed below, the chest REFFS can be determined from the accelerometer's signal supplied by theactivity sensing unit 54. - To extract the chest REFFS from the impedance signal supplied by the
impedance measurement unit 60, thecontrol unit 50 may apply morphological operators as discussed in - U.S. Pat. No. 8,419,645 B2. U.S. Pat. No. 8,419,645 B2 describes how morphological operators can be utilized to determine respiration parameters from a transthoracic impedance signal. Although the measuring configuration disclosed in U.S. Pat. No. 8,419,645 B2 is different from the one described herein, and does not utilize transthoracic impedance given the relative position of the
lead 100 with respect to theIPG 106, the method disclosed in U.S. Pat. No. 8,419,645 B2 (particularly at column 9, line 5 to column 10,line 26, and inFIGS. 2-5 ) can be applied in an analogous manner. - The
control unit 50 may be further connected to amemory unit 70 that may serve to store signals recorded bycontrol unit 50, and/or programs that control the operation ofcontrol unit 50. - In order to wirelessly communicate recorded signals to an external device or to receive program instructions, a
telemetry unit 72 is also connected to thecontrol unit 50. -
FIG. 4 shows a more detailed sketch of the implantedmulti-electrode lead 100 in the left superiorintercostal vein 101, and of the crossing of thephrenic nerve 103 and thecardiac branches 200 of thevagus nerve 104. Since the objective is to stimulate thesevagus nerve branches 200 and thephrenic nerve 103, and both typically cross anteriorly to thevein 101, eachcontact area 201 of thelead 100 preferably presents anactive area 202 for stimulation and an opposite insulated area 203 (e.g. half of a ring contact may be coated with parylene or another insulator). Thelead 100 can be rotated and implanted so theactive areas 202 face thephrenic nerve 103 and thecardiac branches 200. This minimizes unwanted stimulation of thelaryngeal nerve branches 204, which form part of thevagus nerve 104 near thevein 101 crossing. Theanchoring mechanism 105 of thelead 100 may utilizeelastic loops 205 similar to those employed in embolic protection devices. -
FIG. 5 illustrates an alternative version of thelead 100 wherein thecontact areas 201 of fourdistal electrodes 107 are each implemented with opposingactive areas 202 separated by insulatingareas 203. In yet another alternative version for thelead 100, the fourdistal electrodes 107 each include threeactive areas 202 separated by insulatingareas 203. These alternative lead designs allow for improved stimulation selectivity of thecardiac branches 200 due to anatomical variations that may occur in the branching from the mainvagus nerve trunk 104. -
FIG. 6 illustrates a preferred stimulation arrangement for theelectrodes 107. Afirst group 400 ofelectrodes 107 implements a guarded-cathode configuration for the stimulation of thephrenic nerve 103 whereas asecond group 401 ofelectrodes 107 does the same for the stimulation of the vagus nervecardiac branches 200. The stimulation is preferably current-based and is not delivered simultaneously, i.e. Vagus Nerve Stimulation (VNS) is delivered during normal breathing (as discussed below), and is interrupted whenhypopnea 506 or apnea events 507 (seeFIG. 7 ) are detected from the chest Respiration Effort Signal (REFFS). -
FIG. 7 illustrates that the chest REFFS in a CHF patient with CSA alternates between two breathing patterns. Thetop pattern 500 represents normal breathing, whereas the bottom 501, known as the Cheyne-Stokes respiration pattern, is typically observed at sleep. - The chest REFFS Amplitude can be proportional to gravitational acceleration (∝g) if an accelerometer in the
IPG 106 is used, or proportional to ohms (Ω) if impedance measurement between the IPG'scase 20 and anelectrode 107 in thelead 100 is utilized instead. Normal breathing alternates periods ofinspiration 502 andexpiration 503, with a breathepause 504 in between, and with a minimum REFFS peak-to-peak amplitude 505 indicative of the patient's normal tidal volume. - The chest REFFS may be obtained by first band-pass filtering the accelerometer or impedance signal between 0.1 Hz and 0.5 Hz.
FIG. 8 (which is adapted from Rendon et al. “Mapping the Human Body for Vibrations using an Accelerometer”, Proceedings of the 29th Annual IEEE EMBS International Conference, FrA06.1, pp. 1671-4, 2007) shows that the mean power at theIPG 106 implant sites (i.e. somewhere around 9-a and 10-a) is 20 dB below the maximum measured at the 11-a position (ideal chest position). Hence, signal processing for extraction of the chest REFFS may involve a morphological filter algorithm given the reduced signal-to-noise ratio. In an alternative version, signal processing for extraction of the chest REFFS is based on discrete wavelet transforms. In this case, combining signals from both the accelerometer signal supplied by theactivity sensing unit 54 and the far-field electrogram (ff-EGM) 600 may increase the accuracy of event classification compared to use of only the accelerometer signal. - Vagus Nerve Stimulation (VNS) therapy preferably consists of a programmable train of one or more pulses with a fixed charge per pulse, and a fixed frequency between them, delivered in anticipation of a physiological event in the respiration pattern that can be predicted from the chest Respiration Effort Signal (REFFS). In a preferred version, the beginning of the delivery of the VNS train of pulses occurs during the
breathing pause period 504. Given the delay between Phrenic Nerve Stimulation (PhrNS) and contraction of the diaphragm muscle, this feed-forward control permits any VNS stimulation spillage to the phrenic nerve (should it occur) to appear at theinspiration period 502, thereby providing breathing assistance for the patient. VNS may be duty cycled and delivered intermittently, i.e. once every “n” breathingpause periods 504, and might only be active during pre-programmed daily sessions. - When the
chest REFFS amplitude 505 drops, ahypopnea event 506 may be declared by a detection algorithm in theIPG 106, and PhrNS therapy may be started during the nextbreathing pause period 504. To directly detect the initiation ofapnea events 507, aprogrammable timer 508 from the onset of each inspiration period 502 (normal breathing 500 established) allows starting PhrNS therapy if the following onset ofinspiration period 502 cannot be derived from the chest REFFS before thetimer 508 elapses. - Vagus Nerve Stimulation (VNS) and Phrenic Nerve Stimulation (PhrNS) are preferably delivered multiplexed in time, and PhrNS has priority over VNS, i.e. if VNS is being delivered and either a
hypopnea 506 or anapnea 507 condition is detected from the chest REFFS, then VNS may be aborted until PhrNS restoresnormal breathing 500. - Phrenic Nerve Stimulation (PhrNS) therapy preferably consists of a programmable train of pulses of similar frequency compared to VNS (tens of Hz). However, each train may include a ramp up phase, both in charge injected per pulse and in frequency between pulses, and a ramp down phase. This type of train allows for a more natural recruitment of the diaphragm. Once PhrNS successfully assists restoration of the chest REFFS to the peak-to-
peak amplitude 505, the stimulation is stopped (and the chest REFFS monitoring is continued). - The
IPG 106 might operate in a stimulation mode where the chest Respiration Effort Signal (REFFS) is also used as feed-forward parameter for the delivery of Phrenic Nerve Stimulation (PhrNS) therapy. This mode might be triggered by the patient or clinician (as by placing a magnet near the IPG 106) if, for example, the patient is hospitalized and placed on mechanical ventilation. Phrenic Nerve Stimulation (PhrNS) may minimize diaphragm atrophy, and may therefore accelerate the period during which the patient is weaned off ventilation. This mode does not prevent Vagus Nerve Stimulation (VNS) therapy from being delivered, as it can be time-multiplexed with PhrNS. - The triaxial accelerometer might also be used to extract sleeping position patterns. For example, a decrease in the patient sleeping angle may indicate improvement of the patient's condition, as patients with CHF tend to sleep with several pillows due to breathing difficulties associated with the disease (owing to the lungs filling with fluid).
- Returning to
FIG. 2 , the far-field electrogram (ff-EGM) 600 is recorded between anelectrode 107 in thelead 100 and the IPG'scase 20. Diagnostics and statistics such as sleeping angles, apnea events, arrhythmias, etc. can be wirelessly communicated to thebedside Patient Messenger 601 via a MICS-band link 602, which can further relay the information to a Home Monitoring/Remote Programming Center. Asimilar link 603 allows aProgrammer 604 to program theIPG 106. - A few of the advantages achieved by the invention are:
- 1) only a single endovascular lead for dual Vagus-Phrenic Nerve Stimulation is needed, with reduced side effects;
- 2) the system is implantable via standard pacemaker techniques and tools, thereby reducing risk and physician training requirements;
- 3) the system avoids leads through the SVC/heart chambers, and is therefore compatible with other CRM devices;
- 4) the system can provide assistive breathing therapy for CHF patients admitted to the hospital and placed on mechanical ventilation;
- 5) the system offers added diagnostics/statistics for CHF patients suffering from CSA; and
- 6) the system provides improved therapy for CHF patients suffering from CSA.
- It is emphasized that the foregoing versions of the invention are merely exemplary, and they can be modified in various respects. In particular, it is possible for
IPG 106 to utilize alternative methods of stimulation, e.g., voltage-based stimulation. It is also possible for thelead 100 to includeadditional electrodes 107 that are situated in the access vein when thelead 100 is implanted as described above. Such additional electrodes may also permit stimulating the vagus and phrenic nerves transvascularly through the access vein's wall. This feature may further improve stimulation selectivity. This invention can readily be adapted to a number of different kinds of nerve stimulation devices and nerve stimulation methods by use of the concepts discussed herein. - The invention is not intended to be limited to the exemplary versions discussed above, but rather is intended to be limited only by the claims set out below. Thus, the invention encompasses all different versions that fall literally or equivalently within the scope of these claims.
Claims (20)
1. An implantable pulse generator (106) connected or connectable to a stimulation lead (100) having a stimulation electrode (107), the implantable pulse generator (106) including:
a. a respiration activity sensing unit (54, 60) configured to generate a signal representing respiration activity,
b. a control unit (50) configured to trigger delivery of nerve stimulation electrical pulses via the stimulation electrode (107), wherein triggering of delivery depends on the signal representing respiration activity.
2. The implantable pulse generator (106) of claim 1 wherein the control unit (50) is configured to:
a. generate a predictive respiration pattern from the signal representing respiration activity, and
b. trigger the stimulation pulses in dependence on the predictive respiration pattern.
3. The implantable pulse generator (106) of claim 1 :
a. further including the stimulation lead (100), wherein the stimulation lead (100) has several stimulation electrodes (107),
b. the control unit (50) is configured to:
(1) select one or more of the stimulation electrodes (107), and
(2) trigger delivery of nerve stimulation electrical pulses via the selected electrodes (107).
4. The implantable pulse generator (106) of claim 3 wherein at least some of the stimulation electrodes (107) are situated in a left superior intercostal vein (101) between a phrenic nerve (103) and a vagus nerve (104).
5. The implantable pulse generator (106) of claim 3 wherein one or more of the stimulation electrodes (107) extend about no more than half of the outer circumference of the stimulation lead (100).
6. The implantable pulse generator (106) of claim 1 wherein the control unit (50) is configured to trigger delivery of nerve stimulation electrical pulses when the signal representing respiration activity indicates a breathing pause.
7. The implantable pulse generator (106) of claim 1 wherein the control unit (50) is configured to trigger delivery of nerve stimulation electrical pulses when the signal representing respiration activity indicates decreased inspiration and expiration amplitudes.
8. The implantable pulse generator (106) of claim 1 wherein the signal representing respiration activity is a chest Respiration Effort Signal (REFFS).
9. The implantable pulse generator (106) of claim 8 wherein the respiration activity sensing unit (54):
a. includes or is connected to an accelerometer, and
b. is configured to generate the chest Respiration Effort Signal (REFFS) from a signal from the accelerometer.
10. The implantable pulse generator (106) of claim 1 wherein the respiration activity sensing unit (60):
a. includes or is connected to an impedance measurement unit (60) configured to generate an impedance signal representing intrathoracic impedance, and
b. is configured to generate the chest Respiration Effort Signal (REFFS) from the impedance signal.
11. The implantable pulse generator (106) of claim 1 further including a telemetry unit (72) configured to:
a. receive programming, and/or
b. transmit recorded data and/or status information.
12. The implantable pulse generator (106) of claim 1 further including a heart monitoring unit that is configured to determine at least a heart rate.
13. The implantable pulse generator (106) of claim 1 further including:
a. a case (20) enclosing at least a portion of the implantable pulse generator (106), wherein at least a portion of the case is electrically conductive;
b. a far-field electrogram (ff-EGM) sensing unit (56) connected to:
(1) the case (20), and
(2) a stimulation electrode (107) of the stimulation lead (100), the far-field electrogram (ff-EGM) sensing unit (56) being configured to sense ff-EGM (600) signals.
14. The implantable pulse generator (106) of claim 1 :
a. further including the stimulation lead (100),
b. wherein the stimulation lead (100) is a multi-electrode lead configured for placement in a left superior intercostal vein.
15. A method for nerve stimulation including the steps of:
a. sensing respiration activity,
b. delivering nerve stimulation electrical pulses via a stimulation electrode (107), wherein delivery is dependent on the sensed respiration activity.
16. The method of claim 15 :
a. further including the step of determining a predictive respiration pattern based on the sensed respiration activity, and
b. wherein the delivery of the nerve stimulation electrical pulses is also dependent on the predictive respiration pattern.
17. The method of claim 15 wherein the nerve stimulation electrical pulses are delivered to a vagus nerve and/or a phrenic nerve.
18. The method of claim 15 wherein the nerve stimulation electrical pulses are delivered during a breathing pause (504).
19. The method of claim 15 wherein:
a. the nerve stimulation electrical pulses are delivered via several stimulation electrodes (107) on a stimulation lead (100),
b. the several stimulation electrodes (107) are situated:
(1) in a left superior intercostal vein (101),
(2) between a phrenic nerve (103) and a vagus nerve (104).
20. An implantable pulse generator (106)
a. a respiration activity sensing unit (54, 60) configured to generate a signal representing respiration activity;
b. a stimulation lead (100) having a stimulation electrode (107) situated within a left superior intercostal vein between a phrenic nerve (103) and a vagus nerve (104);
d. a control unit (50) configured to trigger delivery of electric stimulation pulses via the stimulation electrode (107) when the signal representing respiration activity indicates a breathing pause.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/018,973 US20160256692A1 (en) | 2015-03-03 | 2016-02-09 | Combined vagus-phrenic nerve stimulation device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127296P | 2015-03-03 | 2015-03-03 | |
US15/018,973 US20160256692A1 (en) | 2015-03-03 | 2016-02-09 | Combined vagus-phrenic nerve stimulation device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160256692A1 true US20160256692A1 (en) | 2016-09-08 |
Family
ID=55304881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/018,973 Abandoned US20160256692A1 (en) | 2015-03-03 | 2016-02-09 | Combined vagus-phrenic nerve stimulation device |
US15/041,150 Active US10143844B2 (en) | 2015-03-03 | 2016-02-11 | Nerve stimulation systems via endovascular leads |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/041,150 Active US10143844B2 (en) | 2015-03-03 | 2016-02-11 | Nerve stimulation systems via endovascular leads |
Country Status (2)
Country | Link |
---|---|
US (2) | US20160256692A1 (en) |
EP (1) | EP3064131A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190001126A1 (en) * | 2017-06-30 | 2019-01-03 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10391314B2 (en) | 2014-01-21 | 2019-08-27 | Lungpacer Medical Inc. | Systems and related methods for optimization of multi-electrode nerve pacing |
US10406367B2 (en) | 2012-06-21 | 2019-09-10 | Lungpacer Medical Inc. | Transvascular diaphragm pacing system and methods of use |
US10471250B2 (en) | 2016-08-05 | 2019-11-12 | Cardiac Pacemakers, Inc. | Pacemakers for implant in the internal thoracic vasculature with communication to other implantable devices |
CN110496309A (en) * | 2019-08-22 | 2019-11-26 | 西安八水健康科技有限公司 | A kind of respiration gate control vagal stimulation system and device |
US10512772B2 (en) | 2012-03-05 | 2019-12-24 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10537731B2 (en) | 2016-11-17 | 2020-01-21 | Cardiac Pacemakers, Inc. | Transvenous mediastinum access for the placement of cardiac pacing and defibrillation electrodes |
US10561843B2 (en) | 2007-01-29 | 2020-02-18 | Lungpacer Medical, Inc. | Transvascular nerve stimulation apparatus and methods |
US10646720B2 (en) | 2016-11-17 | 2020-05-12 | Cardiac Pacemakers, Inc. | Parasternal placement of an active medical device using the internal thoracic vasculature |
US10675476B2 (en) | 2016-12-22 | 2020-06-09 | Cardiac Pacemakers, Inc. | Internal thoracic vein placement of a transmitter electrode for leadless stimulation of the heart |
US10751543B2 (en) | 2016-12-22 | 2020-08-25 | Cardiac Pacemakers, Inc. | Azygos, internal thoracic, and/or intercostal vein implantation and use of medical devices |
US10786679B2 (en) | 2016-12-21 | 2020-09-29 | Cardiac Pacemakers, Inc. | Lead with integrated electrodes |
US10806932B2 (en) | 2017-03-20 | 2020-10-20 | Cardiac Pacemakers, Inc. | Implantable medical device |
US10850067B2 (en) | 2016-12-21 | 2020-12-01 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the intercostal vein |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US10980570B2 (en) | 2017-01-12 | 2021-04-20 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US10987511B2 (en) | 2018-11-08 | 2021-04-27 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11020075B2 (en) | 2017-05-12 | 2021-06-01 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US11077299B2 (en) | 2017-03-07 | 2021-08-03 | Cardiac Pacemakers, Inc. | Implantation of an active medical device |
US11077297B2 (en) | 2017-04-18 | 2021-08-03 | Cardiac Pacemakers, Inc. | Active medical device with attachment features |
US11324950B2 (en) | 2016-04-19 | 2022-05-10 | Inspire Medical Systems, Inc. | Accelerometer-based sensing for sleep disordered breathing (SDB) care |
US11357979B2 (en) | 2019-05-16 | 2022-06-14 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11707619B2 (en) | 2013-11-22 | 2023-07-25 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US11738197B2 (en) | 2019-07-25 | 2023-08-29 | Inspire Medical Systems, Inc. | Systems and methods for operating an implantable medical device based upon sensed posture information |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116456B2 (en) * | 2019-06-27 | 2021-09-14 | Medtronic, Inc. | Sensing for heart failure management |
WO2023205654A2 (en) * | 2022-04-18 | 2023-10-26 | The Regents Of The University Of California | System and method for transvascular therapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085866A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | Breathing disorder and precursor predictor and therapy delivery device and method |
US20060155341A1 (en) * | 2003-10-15 | 2006-07-13 | Tehrani Amir J | Device and method for biasing lung volume |
US20100036451A1 (en) * | 2007-01-29 | 2010-02-11 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
US7747323B2 (en) * | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7979128B2 (en) * | 2003-10-15 | 2011-07-12 | Rmx, Llc | Device and method for gradually controlling breathing |
US7155295B2 (en) * | 2003-11-07 | 2006-12-26 | Paracor Medical, Inc. | Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing |
US7587238B2 (en) * | 2005-03-11 | 2009-09-08 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
US8630704B2 (en) | 2007-06-25 | 2014-01-14 | Cardiac Pacemakers, Inc. | Neural stimulation with respiratory rhythm management |
US9199075B1 (en) | 2008-02-07 | 2015-12-01 | Respicardia, Inc. | Transvascular medical lead |
US20090275996A1 (en) | 2008-04-30 | 2009-11-05 | Medtronic, Inc. | Techniques for placing medical leads for electrical stimulation of nerve tissue |
US8419645B2 (en) | 2008-10-16 | 2013-04-16 | Biotronik Crm Patent Ag | Respiration measurement by means of morphological operators |
US8897879B2 (en) * | 2011-11-04 | 2014-11-25 | Medtronic, Inc. | Method and apparatus for therapies of the cardiovascular and cardiorenal system |
-
2016
- 2016-02-03 EP EP16154006.7A patent/EP3064131A1/en not_active Withdrawn
- 2016-02-09 US US15/018,973 patent/US20160256692A1/en not_active Abandoned
- 2016-02-11 US US15/041,150 patent/US10143844B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085866A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | Breathing disorder and precursor predictor and therapy delivery device and method |
US20060155341A1 (en) * | 2003-10-15 | 2006-07-13 | Tehrani Amir J | Device and method for biasing lung volume |
US7747323B2 (en) * | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US20100036451A1 (en) * | 2007-01-29 | 2010-02-11 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10765867B2 (en) | 2007-01-29 | 2020-09-08 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10792499B2 (en) | 2007-01-29 | 2020-10-06 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10864374B2 (en) | 2007-01-29 | 2020-12-15 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10561843B2 (en) | 2007-01-29 | 2020-02-18 | Lungpacer Medical, Inc. | Transvascular nerve stimulation apparatus and methods |
US11027130B2 (en) | 2007-01-29 | 2021-06-08 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US11369787B2 (en) | 2012-03-05 | 2022-06-28 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10512772B2 (en) | 2012-03-05 | 2019-12-24 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10589097B2 (en) | 2012-06-21 | 2020-03-17 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US10406367B2 (en) | 2012-06-21 | 2019-09-10 | Lungpacer Medical Inc. | Transvascular diaphragm pacing system and methods of use |
US11357985B2 (en) | 2012-06-21 | 2022-06-14 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US10561844B2 (en) | 2012-06-21 | 2020-02-18 | Lungpacer Medical Inc. | Diaphragm pacing systems and methods of use |
US11707619B2 (en) | 2013-11-22 | 2023-07-25 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10391314B2 (en) | 2014-01-21 | 2019-08-27 | Lungpacer Medical Inc. | Systems and related methods for optimization of multi-electrode nerve pacing |
US11311730B2 (en) | 2014-01-21 | 2022-04-26 | Lungpacer Medical Inc. | Systems and related methods for optimization of multi-electrode nerve pacing |
US11324950B2 (en) | 2016-04-19 | 2022-05-10 | Inspire Medical Systems, Inc. | Accelerometer-based sensing for sleep disordered breathing (SDB) care |
US10576267B2 (en) | 2016-08-05 | 2020-03-03 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US11534602B2 (en) | 2016-08-05 | 2022-12-27 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US10471250B2 (en) | 2016-08-05 | 2019-11-12 | Cardiac Pacemakers, Inc. | Pacemakers for implant in the internal thoracic vasculature with communication to other implantable devices |
US10537731B2 (en) | 2016-11-17 | 2020-01-21 | Cardiac Pacemakers, Inc. | Transvenous mediastinum access for the placement of cardiac pacing and defibrillation electrodes |
US10646720B2 (en) | 2016-11-17 | 2020-05-12 | Cardiac Pacemakers, Inc. | Parasternal placement of an active medical device using the internal thoracic vasculature |
US10786679B2 (en) | 2016-12-21 | 2020-09-29 | Cardiac Pacemakers, Inc. | Lead with integrated electrodes |
US10850067B2 (en) | 2016-12-21 | 2020-12-01 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the intercostal vein |
US11464990B2 (en) | 2016-12-22 | 2022-10-11 | Cardiac Pacemakers, Inc. | Azygos, internal thoracic, and/or intercostal vein implantation and use of medical devices |
US10675476B2 (en) | 2016-12-22 | 2020-06-09 | Cardiac Pacemakers, Inc. | Internal thoracic vein placement of a transmitter electrode for leadless stimulation of the heart |
US10751543B2 (en) | 2016-12-22 | 2020-08-25 | Cardiac Pacemakers, Inc. | Azygos, internal thoracic, and/or intercostal vein implantation and use of medical devices |
US10980570B2 (en) | 2017-01-12 | 2021-04-20 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US11077299B2 (en) | 2017-03-07 | 2021-08-03 | Cardiac Pacemakers, Inc. | Implantation of an active medical device |
US10806932B2 (en) | 2017-03-20 | 2020-10-20 | Cardiac Pacemakers, Inc. | Implantable medical device |
US11077297B2 (en) | 2017-04-18 | 2021-08-03 | Cardiac Pacemakers, Inc. | Active medical device with attachment features |
US11020075B2 (en) | 2017-05-12 | 2021-06-01 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US20190001126A1 (en) * | 2017-06-30 | 2019-01-03 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
US11883658B2 (en) * | 2017-06-30 | 2024-01-30 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
US11090489B2 (en) | 2017-08-02 | 2021-08-17 | Lungpacer Medical, Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10926087B2 (en) | 2017-08-02 | 2021-02-23 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US11944810B2 (en) | 2017-08-04 | 2024-04-02 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US10987511B2 (en) | 2018-11-08 | 2021-04-27 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11717673B2 (en) | 2018-11-08 | 2023-08-08 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11890462B2 (en) | 2018-11-08 | 2024-02-06 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11357979B2 (en) | 2019-05-16 | 2022-06-14 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
US11738197B2 (en) | 2019-07-25 | 2023-08-29 | Inspire Medical Systems, Inc. | Systems and methods for operating an implantable medical device based upon sensed posture information |
CN110496309A (en) * | 2019-08-22 | 2019-11-26 | 西安八水健康科技有限公司 | A kind of respiration gate control vagal stimulation system and device |
Also Published As
Publication number | Publication date |
---|---|
EP3064131A1 (en) | 2016-09-07 |
US10143844B2 (en) | 2018-12-04 |
US20160256687A1 (en) | 2016-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160256692A1 (en) | Combined vagus-phrenic nerve stimulation device | |
US20170326369A1 (en) | Trans septal implantable medical device | |
US8386038B2 (en) | Vagal stimulation during atrial tachyarrhythmia to facilitate cardiac resynchronization therapy | |
US8386053B2 (en) | Subclavian ansae stimulation | |
US9254389B2 (en) | Electrical inhibition of the phrenic nerve during cardiac pacing | |
US9295846B2 (en) | Muscle and nerve stimulation | |
EP1588735B1 (en) | System for applying electrical therapy during hyperpnea phase of periodic breathing using an implantable medical device | |
US6415183B1 (en) | Method and apparatus for diaphragmatic pacing | |
JP5039151B2 (en) | System for treating supraventricular arrhythmia | |
US7672729B2 (en) | Multi-variable feedback control of stimulation for inspiratory facilitation | |
US8903489B2 (en) | Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device | |
US20030195571A1 (en) | Method and apparatus for the treatment of central sleep apnea using biventricular pacing | |
US20120095521A1 (en) | Detection of heart rhythm using an accelerometer | |
US7519426B1 (en) | Techniques for reducing orthostatic hypotension | |
US20130289636A1 (en) | Timed implantable therapy delivery device | |
US8214033B2 (en) | Interferential cardiac preconditioning and depolarization | |
EP3720355B1 (en) | Sensor-based phrenic nerve stimulation detection | |
US20230241391A1 (en) | Integrated sleep apnea and at least one of cardiac monitoring and cardiac therapy | |
CN116531660A (en) | Integrated sleep apnea and at least one of cardiac monitoring and cardiac therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOTRONIK SE & CO. KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARU, MARCELO;REEL/FRAME:037709/0253 Effective date: 20150302 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |